The role of dolutegravir in antiretroviral therapy

Detalhes bibliográficos
Autor(a) principal: Vieira, Tamyres dos Santos
Data de Publicação: 2019
Outros Autores: Vieira, Isabela dos Santos, Bresser, Matheus, Moura, Letícia Coutinho Lopes, Moura, Marcos de Assis
Tipo de documento: Artigo
Idioma: por
Título da fonte: HU Revista (Online)
Texto Completo: https://periodicos.ufjf.br/index.php/hurevista/article/view/13945
Resumo: Integrase inhibitors are the newest class of approved antiretroviral drugs that act by preventing the incorporation of HIV DNA into the CD4 + T lymphocyte (LTCD4 +) genome of the host, limiting the spread of the virus. Dolutegravir and the most modern integrase inhibitor and like the other inhibitors presents high performance, good tolerance; high genetic barrier for resistance mutations, in addition to being effective in patients already submitted to previous antiretroviral treatment. In this context, the present study is a bibliographical review study conducted from January to June, 2018, of scientific papers on scientific articles dealing with exclusive aspects of dolutegravir in antiretroviral therapy compared to other therapeutic regimens. Concluding that dolutegravir treatment has the main advantages of rapid virological suppression; good tolerance and high genetic barrier for resistance mutations.
id UFJF-8_c51f11a692c700fce2e47a620c0c51c1
oai_identifier_str oai:periodicos.ufjf.br:article/13945
network_acronym_str UFJF-8
network_name_str HU Revista (Online)
repository_id_str
spelling The role of dolutegravir in antiretroviral therapyO papel do dolutegravir na terapia antiretroviralHIVHigh Activity Antiretroviral TherapyAcquired Immunodeficiency SyndromeViral LoadDolutegravirHIVTerapia Antirretroviral de Alta AtividadeSíndrome de Imunodeficiência AdquiridaCarga ViralDolutegravirIntegrase inhibitors are the newest class of approved antiretroviral drugs that act by preventing the incorporation of HIV DNA into the CD4 + T lymphocyte (LTCD4 +) genome of the host, limiting the spread of the virus. Dolutegravir and the most modern integrase inhibitor and like the other inhibitors presents high performance, good tolerance; high genetic barrier for resistance mutations, in addition to being effective in patients already submitted to previous antiretroviral treatment. In this context, the present study is a bibliographical review study conducted from January to June, 2018, of scientific papers on scientific articles dealing with exclusive aspects of dolutegravir in antiretroviral therapy compared to other therapeutic regimens. Concluding that dolutegravir treatment has the main advantages of rapid virological suppression; good tolerance and high genetic barrier for resistance mutations.Os inibidores da integrase são a mais nova classe de antirretroviral aprovada, que agem impedindo a incorporação do DNA do HIV no genoma do linfócito T CD4+ (LTCD4+) do hospedeiro, limitando a propagação do vírus. O Dolutegravir e o inibidor da integrase mais moderno e como os demais inibidores apresenta de alta performance, boa tolerância; alta barreira genética para mutações de resistência, além de apresentar eficácia em pacientes já submetidos a tratamento antirretroviral anterior. Neste contexto o presente estudo trata-se de um estudo de revisão bibliográfica realizada de janeiro a junho de 2018, de artigos científicos de artigos científicos que abordam aspectos exclusivos do dolutegravir na terapia antirretroviral em comparação com outros esquemas terapêuticos. Concluindo que o tratamento com dolutegravir apresenta como principais vantagens à rápida supressão virológica; boa tolerância e alta barreira genética para mutações de resistência.Editora UFJF2019-06-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtRevLitapplication/pdfhttps://periodicos.ufjf.br/index.php/hurevista/article/view/1394510.34019/1982-8047.2018.v44.13945HU Revista; v. 44 n. 3 (2018): Doenças Infecciosas: epidemiologia, prevenção e controle; 379 - 3851982-80470103-3123reponame:HU Revista (Online)instname:Universidade Federal de Juiz de Fora (UFJF)instacron:UFJFporhttps://periodicos.ufjf.br/index.php/hurevista/article/view/13945/18769Vieira, Tamyres dos SantosVieira, Isabela dos SantosBresser, MatheusMoura, Letícia Coutinho LopesMoura, Marcos de Assisinfo:eu-repo/semantics/openAccess2019-07-19T03:00:20Zoai:periodicos.ufjf.br:article/13945Revistahttps://periodicos.ufjf.br/index.php/hurevistaPUBhttps://periodicos.ufjf.br/index.php/hurevista/oairevista.hurevista@ufjf.edu.br1982-80470103-3123opendoar:2019-07-19T03:00:20HU Revista (Online) - Universidade Federal de Juiz de Fora (UFJF)false
dc.title.none.fl_str_mv The role of dolutegravir in antiretroviral therapy
O papel do dolutegravir na terapia antiretroviral
title The role of dolutegravir in antiretroviral therapy
spellingShingle The role of dolutegravir in antiretroviral therapy
Vieira, Tamyres dos Santos
HIV
High Activity Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Viral Load
Dolutegravir
HIV
Terapia Antirretroviral de Alta Atividade
Síndrome de Imunodeficiência Adquirida
Carga Viral
Dolutegravir
title_short The role of dolutegravir in antiretroviral therapy
title_full The role of dolutegravir in antiretroviral therapy
title_fullStr The role of dolutegravir in antiretroviral therapy
title_full_unstemmed The role of dolutegravir in antiretroviral therapy
title_sort The role of dolutegravir in antiretroviral therapy
author Vieira, Tamyres dos Santos
author_facet Vieira, Tamyres dos Santos
Vieira, Isabela dos Santos
Bresser, Matheus
Moura, Letícia Coutinho Lopes
Moura, Marcos de Assis
author_role author
author2 Vieira, Isabela dos Santos
Bresser, Matheus
Moura, Letícia Coutinho Lopes
Moura, Marcos de Assis
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Vieira, Tamyres dos Santos
Vieira, Isabela dos Santos
Bresser, Matheus
Moura, Letícia Coutinho Lopes
Moura, Marcos de Assis
dc.subject.por.fl_str_mv HIV
High Activity Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Viral Load
Dolutegravir
HIV
Terapia Antirretroviral de Alta Atividade
Síndrome de Imunodeficiência Adquirida
Carga Viral
Dolutegravir
topic HIV
High Activity Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Viral Load
Dolutegravir
HIV
Terapia Antirretroviral de Alta Atividade
Síndrome de Imunodeficiência Adquirida
Carga Viral
Dolutegravir
description Integrase inhibitors are the newest class of approved antiretroviral drugs that act by preventing the incorporation of HIV DNA into the CD4 + T lymphocyte (LTCD4 +) genome of the host, limiting the spread of the virus. Dolutegravir and the most modern integrase inhibitor and like the other inhibitors presents high performance, good tolerance; high genetic barrier for resistance mutations, in addition to being effective in patients already submitted to previous antiretroviral treatment. In this context, the present study is a bibliographical review study conducted from January to June, 2018, of scientific papers on scientific articles dealing with exclusive aspects of dolutegravir in antiretroviral therapy compared to other therapeutic regimens. Concluding that dolutegravir treatment has the main advantages of rapid virological suppression; good tolerance and high genetic barrier for resistance mutations.
publishDate 2019
dc.date.none.fl_str_mv 2019-06-21
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
ArtRevLit
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://periodicos.ufjf.br/index.php/hurevista/article/view/13945
10.34019/1982-8047.2018.v44.13945
url https://periodicos.ufjf.br/index.php/hurevista/article/view/13945
identifier_str_mv 10.34019/1982-8047.2018.v44.13945
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://periodicos.ufjf.br/index.php/hurevista/article/view/13945/18769
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Editora UFJF
publisher.none.fl_str_mv Editora UFJF
dc.source.none.fl_str_mv HU Revista; v. 44 n. 3 (2018): Doenças Infecciosas: epidemiologia, prevenção e controle; 379 - 385
1982-8047
0103-3123
reponame:HU Revista (Online)
instname:Universidade Federal de Juiz de Fora (UFJF)
instacron:UFJF
instname_str Universidade Federal de Juiz de Fora (UFJF)
instacron_str UFJF
institution UFJF
reponame_str HU Revista (Online)
collection HU Revista (Online)
repository.name.fl_str_mv HU Revista (Online) - Universidade Federal de Juiz de Fora (UFJF)
repository.mail.fl_str_mv revista.hurevista@ufjf.edu.br
_version_ 1796798242506145792

Registros relacionados